Drug Shortage Report for TRAVASOL
Report ID | 147113 |
Drug Identification Number | 00872296 |
Brand name | TRAVASOL |
Common or Proper name | 10% Amino acids (Blend C) injection |
Company Name | BAXTER CORPORATION |
Market Status | MARKETED |
Active Ingredient(s) | LEUCINE SERINE TYROSINE PROLINE ARGININE GLYCINE L-ALANINE TRYPTOPHAN THREONINE HISTIDINE VALINE ISOLEUCINE L-LYSINE METHIONINE PHENYLALANINE |
Strength(s) | 730MG 500MG 40MG 680MG 1.15G 1.03G 2.07G 180MG 420MG 480MG 580MG 600MG 580MG 400MG 560MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 3000mL (JB6583) |
ATC code | B05BA |
ATC description | I.V. SOLUTIONS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2021-10-13 |
Actual start date | 2021-10-13 |
Estimated end date | 2021-11-04 |
Actual end date | 2021-11-04 |
Shortage status | Resolved |
Updated date | 2021-11-05 |
Company comments | Baxter is experiencing supply constraints on Travasol 3L (Baxter Code JB6583) due to manufacturing delays. Get well is expected early November 2021. Please contact your Baxter Nutrition Sales Specialist if you have any questions or require additional information. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 7125 MISSISSAUGA ROAD MISSISSAUGA, ONTARIO CANADA L5N 0C2 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2021-11-05 | English | Compare |
v5 | 2021-11-04 | French | Compare |
v4 | 2021-11-04 | English | Compare |
v3 | 2021-10-14 | English | Compare |
v2 | 2021-10-13 | French | Compare |
v1 | 2021-10-13 | English | Compare |
Showing 1 to 6 of 6